Drugs / Razuprotafib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04511650 | Oct 2020 → Feb 2021 | COVID-19, acute respiratory distress syndrome | EyePoint Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Razuprotafib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04511650 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT04511650 ↗ |